Phil Bates of Cincinnati was the latest in a series of bio-tech scientist to be murdered in cold blood, on August 26 - the night before the crash of Comair Flight 5191 in Lexington, a disaster that left 49 passengers dead.
A magical symbol was left at the scene of the murder.
The names Sonafi Aventis (the bird-flu vaccine *scam* folk), Warren Buffett (who recently bought a chunk of Aventis), Adnan Khashoggi (CIA) are well-known to political researchers ...
Summary of the evidence collated here: Patheon, a Canadian drug company and partner of Aventis, is in desperate financial straits and faces ruin because its operations in Puerto Rico have produced an inventory of unstable drugs. What to do? The drug companies intend to market the tainted drugs, anyways. Bates, a quality control chemist for Patheon, was murdered a month after the decision to release the contaminated product was made by officers of Patheon. Did Phil Bates, a quality control engineer, pose a threat to the company's plan to sell tainted pharmaceuticals? The police have no theories, have established no motive - my own investigation of the corrupt corporate background of Bates' life suggests that it may be business related.
- Alex Constantine
Husband Of School Board Member Shot To Death
Reported by: 9News
Web produced by: Liz Foreman
Photographed by: 9News
First posted: 8/27/2006 8:33:07 AM
Last updated: 8/27/2006 9:58:13 AM
A Cincinnati school board member's husband is dead after being found shot on his front porch Saturday night.
A neighbor told 9News they heard one shot fired, then heard a woman scream around 1 a.m. That neighbor called 911.
Once police arrived to the Rose Hill Avenue home, they found Phillip Bates suffering from a single gunshot wound - he later died at the hospital.
Phillip Bates, 55, was the husband of Melanie Bates.
Melanie and her daughter rode downtown with police after the shooting. There is no word from the family.
There is no word about who shot Phillip Bates or how the shooting happened.
The following is the full text from a Cincinnati Police press release:
CINCINNATI POLICE DEPARTMENT CRIMINAL INVESTIGATION SECTION MEDIA RELEASE August 27, 2006
On August 27, 2006, at 1241 a.m., District Four police officers responded to a reported shooting in the area of Clinton Springs and Rose Hill Lane. Upon arrival, police officers discovered an unconscious white male mortally wounded from a gunshot lying on the front porch of 3937 Rose Hill Avenue.
The victim, identified as Mr. Phillip M. Bates MW 55 (DOB: 2-1-51), was transported to University Hospital where he was pronounced dead....
Medallion Left At Bates Murder Scene May Hold Clue
Reported by: 9News
Web produced by: Neil Relyea
Photographed by: 9News
First posted: 9/4/2006 10:40:24 PM
Last Updated: 9/4/2006 11:15:42 PM
Police hope new evidence will give them a break in the Phillip Bates murder case.
Cincinnati police are hoping that someone will recognize a key chain medallion or pendant left at the scene of the murder.
Police say it is in the shape of a "kokopelli" and that it may have been on a key chain.
Homicide detectives found it at the scene after Bates was shot to death outside his home on Rose Hill Avenue in North Avondale over one week ago.
Husband Of School Board Member Shot To Death
The senselessness of the shooting is what is astounding to his friends because they say there would be no point in harming Phil Bates.
Bates was a chemist for many years and worked in quality assurance at PATHEON Corporation here in Cincinnati.
Khashoggi Connection: On the Patheon Board of directors
[Barrick has long been on cozy terms with the CIA, Adnan Khashoggi, and the Bush Family.]
Patheon is an Aventis Partner
Patheon buys Aventis site in US
16 October 2002 - News Editor
Patheon’s strategic platform launched in US
$30m deal provides 530 pharma manufacturing jobs and introduces a ’second tier’ in outsourcing structure
Patheon Inc. based in Mississauga, Toronto in Canada will provide long-term manufacturing and supply services to Aventis Pharmaceuticals Inc. in a deal where Patheon buys the Aventis pharmaceutical manufacturing and development site located in Cincinnati, Ohio, USA.
The agreement means Patheon provides employment to all 530 employees while continuing to manufacture and supply all Aventis products currently produced at the site.
Patheon will also take over from Aventis existing service contracts with ten third-party pharmaceutical companies.
Bob Tedford, CEO of Patheon Inc. sees the US as an important market for Patheon.
The facility is located on a life sciences campus, which incorporates the University of Cincinnati Genomics Research Institute and a development scale manufacturer of active pharmaceutical ingredients
Projected revenues in the first 12 months of operation will be in the range of US $95 million. About 28% of this will be from manufacturing and supply agreements with Aventis that have an initial term of five years with renewal provisions.
GOVERNOR APPLAUDS PATHEON'S U.S. EXPANSION PLAN
Canadian Drug Company To Acquire Ohio Operation, Hire 150 Researchers
CINCINNATI (October 16, 2002) - Governor Bob Taft today commended Patheon, Inc. of Canada on its plan to invest $62 million to acquire and expand Aventis Pharmeceuticals' operation in Reading (Hamilton County).
[Patheon's Financial Woes are Directly Due to PHARMACEUTICAL QUALITY CONTROL Problems. Philip Bates was a quality control chemist... was his murder related to a contaminated or unstable pharmaceutical product the company, or its partner Aventis, is putting on the market. Read all about it ...]
Patheon's future up in the air as profits plummet
25/09/2006 - Patheon’s move to Puerto Rico is shaping up to be the worst decision the contract manufacturer has ever made, resulting in massive losses in the third quarter of 2006 and leading management to entertain the possibility of a sell-out.
As a result the Canadian company has appointed a special committee to “evaluate strategic and financial alternatives” while putting on hold its search for a new CEO, a tell sign that the sale of the firm is one of the options considered.
Patheon acquired Puerto Rican drug manufacturer MOVA for $350m in late 2004, attracted by Puerto Rico's low corporate tax rate and low labour costs, but has struggled to streamline operations since then.
The most serious problem in the third quarter in Puerto Rico occurred at the Caguas facility, where it was discovered that some batches of an undisclosed product might not achieve their expected shelf life.
Patheon decided to temporarily stop production, and after considering data accumulated from stability studies conducted throughout the month of August, the company took corrective actions and in early September it allowed the release of shipments of finished product representing approximately 90 per cent of the total production volumes.
Meanwhile, an inactive ingredient for a different product made at the Carolina facility was temporarily unavailable, though this did not disrupt the client's inventory and the situation has now been remedied.
Additionally, there has been a year-over-year decline in volumes of a generic product manufactured in Puerto Rico as one of Patheon's clients lost a major account earlier this year, while volumes of Merck's blockbuster cholesterol drug Zocor (simvastatin) have also dropped due to its patent expiration last summer.
All these issues, in conjunction with the cost of corrective action the company had to take to address production issues with Abbott's antibiotic Omnicef (cefdinir), were responsible for earnings before interest, tax, depreciation and amortisation (EBITDA) in Puerto Rico of $3.5m in losses in the third quarter, compared with a positive EBITDA of $4.8m in the same period last year.
Even if it wasn't for Puerto Rico and the $254.7m impairment charge that wiped off Patheon's earnings, the company would have still shown a net loss of $13.6m from a $13.2m net profit a year ago.
This is because the efficiencies and cost savings in Patheon's global manufacturing operations promised last quarter with the launch of a vague “Performance Enhancement Programme” have not yet materialised; as a percentage of revenues, the EBITDA margin was 8.5 per cent in Q3 2006, compared with 14.5 per cent in the same period a year ago.
In Canada for example, gains from higher capacity utilisation, particularly at the Whitby and Toronto York Mills facilities, were small and offset by the impact of the strengthening of the Canadian dollar, so EBIDTA there dropped $0.2m to $6.6m.
Across the pond in Europe, gains in sterile product volumes at the two manufacturing sites in Italy were offset by declines in mature product volumes at Swindon, UK and Bourgoin-Jallieu, France, resulting in an EBITDA of $8.3m, a $1m year-on-year decrease.
Nevertheless, in a conference with financial analysts, Patheon's president Nick DiPietro defended the restructuring scheme.
Even if Patheon is not put up for sale, the company's 5,900 employees who work at 14 facilities in North America and Europe fear that reforms may cut many jobs.
Yet there is some consolation in that revenues jumped 6 per cent to $189.2m, driven by commercial manufacturing services for prescription drugs in Europe, over-the-counter manufacturing in North America and product development services (PDS) growth in both North America and Europe.
In PDS, Patheon's EBITDA was $5.9m, up $1.6m year-on-year, mainly thanks to the Swindon unit where additional laboratory space was brought on line in Q3.
Moreover, the transfer of products into Italy and France from two carve-out initiatives has reached its final stages, while there has also been progress in the construction of a new facility in Swindon dedicated to lyophilized cephalosporins, as the equipment and the operating systems have been fully commissioned, validation batches are expected to be completed in October and the site is on track for commercial production in August 2007.
Looking ahead, Patheon did not issue specific guidance but said that revenues in the fourth quarter of 2006 are expected to be slightly lower than the third quarter.
In Canada, there will be a reduction in volumes at the Whitby facility as the backorder position has been resolved, while in Europe, results will be impacted by normal summer shut downs, the company suggested.
The future in Puerto Rico looks brighter, since shipments have resumed of the product manufactured in Caguas for which stability-related issues had been previously identified and volumes are also expected to increase in Carolina as clients build inventory levels in preparation for the cough and cold season.
Witnesses Likely Saw Phil Bates' Killer
LAST UPDATE: 9/22/2006 11:50:13 AM
Police investigating the murder of Philip Bates three weeks ago now say several people saw his killer and even talked to him before the murder. Some residents in the area were suspicious of the man who hung around near a condo complex near the Bates' home. But as Local 12's Deborah Dixon tells us, no one talked to police until it was too late. Detectives believe Phil Bates' killer hung around the Belvedere Apartments for hours before Philip was killed at his home a street away. A witness at the bus stop said the fidgety African American man who talked to him looked up as Philip Bates pulled into his driveway after midnight on August 27th. Sgt Gary Conner, Cincinnati Homicide Detective: